Published in Cancer on August 06, 2013
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl Immunohistochem Mol Morphol (2015) 1.47
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res (2014) 0.98
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer (2015) 0.93
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res (2014) 0.87
NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol (2015) 0.87
Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. PLoS One (2014) 0.84
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Germline determinants of clinical outcome of cutaneous melanoma. Pigment Cell Melanoma Res (2015) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? PLoS One (2015) 0.78
Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag (2015) 0.77
BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer (2016) 0.77
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs (2016) 0.75
NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget (2016) 0.75
MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. Sci Rep (2017) 0.75
Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma. J Invest Dermatol (2017) 0.75
Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma. Melanoma Res (2017) 0.75
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer (2017) 0.75
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Br J Cancer (2017) 0.75
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Comparison between 1-needle technique versus 2-needle technique for bone marrow aspiration and biopsy procedures. Arch Pathol Lab Med (2013) 2.41
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
The skin allograft revisited: a potentially permanent wound coverage option in the critically ill patient. Plast Reconstr Surg (2009) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res (2010) 2.11
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 2.10
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell (2007) 2.07
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer (2006) 1.93
Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol (2002) 1.92
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One (2010) 1.87
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res (2003) 1.81
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol (2005) 1.76
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol (2006) 1.70
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine (2009) 1.68
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol (2009) 1.66
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol (2002) 1.65
Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol (2003) 1.64
Ethnic differences among patients with cutaneous melanoma. Arch Intern Med (2006) 1.63